Kallikrein Gene Transfer Protects Against Ischemic Stroke by Promoting Glial Cell Migration and Inhibiting Apoptosis
- 1 February 2004
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 43 (2) , 452-459
- https://doi.org/10.1161/01.hyp.0000110905.29389.e5
Abstract
Kallikrein/kinin has been shown to protect against ischemia/reperfusion-induced myocardial infarction and apoptosis. In the present study, we examined the potential neuroprotective action of kallikrein gene transfer in cerebral ischemia. Adult, male Sprague-Dawley rats were subjected to a 1-hour occlusion of the middle cerebral artery followed by intracerebroventricular injection of adenovirus harboring either the human tissue kallikrein gene or the luciferase gene. Kallikrein gene transfer significantly reduced ischemia-induced locomotor deficit scores and cerebral infarction after cerebral ischemia injury. Expression of recombinant human tissue kallikrein was identified and localized in monocytes/macrophages of rat ischemic brain by double immunostaining. Morphological analyses showed that kallikrein gene transfer enhanced the survival and migration of glial cells into the ischemic penumbra and core, as identified by immunostaining with glial fibrillary acidic protein. Cerebral ischemia markedly increased apoptotic cells, and kallikrein gene delivery reduced apoptosis to near-normal levels as seen in sham control rats. In primary cultured glial cells, kinin stimulated cell migration but inhibited hypoxia/reoxygenation-induced apoptosis in a dose-dependent manner. The effects of kinin on both migration and apoptosis were abolished by icatibant, a bradykinin B2 receptor antagonist. Enhanced cell survival after kallikrein gene transfer occurred in conjunction with markedly increased cerebral nitric oxide levels and phospho-Akt and Bcl-2 levels but reduced caspase-3 activation, NAD(P)H oxidase activity, and superoxide production. These results indicate that kallikrein gene transfer provides neuroprotection against cerebral ischemia injury by enhancing glial cell survival and migration and inhibiting apoptosis through suppression of oxidative stress and activation of the Akt–Bcl-2 signaling pathway.Keywords
This publication has 19 references indexed in Scilit:
- LF 16‐0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemiaBritish Journal of Pharmacology, 2003
- Involvement of the Neurotensin Receptor-3 in the Neurotensin-Induced Migration of Human MicrogliaJournal of Neuroscience, 2003
- Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction.Hypertension, 2002
- Impaired endothelium-mediated relaxation in isolated cerebral arteries from insulin-resistant ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2002
- Effect of Hypoxia on Caspase-3, -8, and -9 Activity and Expression in the Cerebral Cortex of Newborn PigletsNeurochemical Research, 2002
- Attenuation of Transient Focal Cerebral Ischemic Injury in Transgenic Mice Expressing a Mutant ICE Inhibitory ProteinJournal of Cerebral Blood Flow & Metabolism, 1997
- Systemic and Portal Vein Delivery of Human Kallikrein Gene Reduces Blood Pressure in Hypertensive RatsHuman Gene Therapy, 1996
- A Fluorometric Assay for the Measurement of Nitrite in Biological SamplesAnalytical Biochemistry, 1993
- Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase.Journal of Clinical Investigation, 1992
- Characterization of monoclonal and polyclonal antibodies to human tissue kallikrein.Hypertension, 1985